[
  {
    "ts": null,
    "headline": "How Investors Are Reacting To Zoetis (ZTS) After Piper Sandler’s Innovation-Lull Downgrade",
    "summary": "Earlier in January, Piper Sandler downgraded Zoetis from Overweight to Neutral, pointing to a potential one- to two-year “innovation lull” and softer consumer spending that could challenge upcoming product launches. Despite this caution, Zoetis continues to emphasize the breadth of its R&D pipeline and its entrenched position across companion and production animal health markets, creating a tension between near-term uncertainty and longer-term product ambitions. Against this backdrop of a...",
    "url": "https://finnhub.io/api/news?id=9ba904f1de29b1bb31ff41181f95510c6d17d5d829616922598167b138c4fca1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769562428,
      "headline": "How Investors Are Reacting To Zoetis (ZTS) After Piper Sandler’s Innovation-Lull Downgrade",
      "id": 138277182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Earlier in January, Piper Sandler downgraded Zoetis from Overweight to Neutral, pointing to a potential one- to two-year “innovation lull” and softer consumer spending that could challenge upcoming product launches. Despite this caution, Zoetis continues to emphasize the breadth of its R&D pipeline and its entrenched position across companion and production animal health markets, creating a tension between near-term uncertainty and longer-term product ambitions. Against this backdrop of a...",
      "url": "https://finnhub.io/api/news?id=9ba904f1de29b1bb31ff41181f95510c6d17d5d829616922598167b138c4fca1"
    }
  }
]